At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The FDA aims to make a decision by April 8, 2026
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
The new site marks the company’s first operation in the region
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Subscribe To Our Newsletter & Stay Updated
